1. Bucillamine-Induced Membranous Nephropathy with Crescent Formation in a Patient with Rheumatoid Arthritis: Case Report and Literature Review
- Author
-
Kosaku Nitta, Shun Manabe, Teruhiro Fujii, Mayuko Banno, Michio Fujiwara, Marie Nakano, Michiyasu Hatano, and Yasuhiko Kita
- Subjects
Membranous nephropathy ,medicine.medical_specialty ,Side effect ,Nephrotic syndrome ,urologic and male genital diseases ,Gastroenterology ,Internal medicine ,Bucillamine ,medicine ,Rapidly progressive glomerulonephritis ,Rheumatoid arthritis ,Proteinuria ,medicine.diagnostic_test ,urogenital system ,business.industry ,medicine.disease ,female genital diseases and pregnancy complications ,Surgery ,Nephrology ,Renal biopsy ,Published online: October, 2014 ,medicine.symptom ,business ,Crescent formation ,medicine.drug - Abstract
Bucillamine is a disease-modifying antirheumatic drug that is structurally similar to D-penicillamine. The major renal side effect of bucillamine and D-penicillamine is proteinuria caused by membranous nephropathy (MN). In addition to MN, combined crescent formation has been occasionally reported in D-penicillamine-induced MN, while crescent formation has been rarely reported in bucillamine-treated cases. Here, we describe a 76-year-old female who presented with nephrotic syndrome and rapidly progressive glomerulonephritis. She was receiving bucillamine as initial treatment for recently diagnosed rheumatoid arthritis, and renal biopsy showed MN with crescent formation. To the best of our knowledge, this is the first report of bucillamine-induced MN with crescent formation in the English literature.
- Published
- 2014
- Full Text
- View/download PDF